[Funding alert] Switzerland-based Alys Pharmaceuticals, Inc. Secures $100Milion in Funding

Co-founded by Medicxi and several world leading dermatology and scientific experts, including John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Nobel Prize winner Craig Mello (UMass Chan Medical School), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology), Alys aspires to redefine the landscape of dermatological treatments.

Read also - Copenhagen-based Pluto.markets Secures €2.4 Million in Funding

The Company is run by co-founder and COO Thibaud Portal (formerly Galderma’s Global Head of Prescription Medicines) and Medicxi’s Francesco De Rubertis serves as Chairman of the Board. Alys believes that emerging indications such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria, will see the next breakthroughs in dermatological advancements.

The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.

Read also - Stockholm-based MANTLE Raises over €2.8 Million in Funding

Alys is working with leading institutions such as Institut Gustave Roussy, UMass Chan Medical School, Icahn School of Medicine at Mount Sinai, Georgia Institute of Technology and Empa, the Swiss Federal Laboratories for Materials Science & Technology, demonstrating its commitment to collaborative research and development.

Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.

Read also - Vilnius-based Axiology Secures €2 Million in Funding

With more than a dozen active programs, Alys anticipates further organic pipeline growth from its cutting-edge platforms, covering inflammatory diseases, autoimmune diseases, dermatology supportive care for cancer patients and rare dermatoses.

Francesco De Rubertis, Chairman of Alys Pharmaceuticals and Partner at Medicxi commented: “We believe that bringing together several asset-centric companies with a phenomenal team will power up Alys to transform innovation in immuno-dermatology. Alys manages a broad pipeline of assets with diverse risk profiles and will hugely benefit from this change of scale and facilitated access to capital.”

Professor John Harris, Chief Innovation Officer of Alys Pharmaceuticals and Chair of Dermatology at UMass Chan Medical School, added: “It is uniquely exciting to oversee such a rich and diverse pipeline, bringing forward modalities that will break new ground in dermatology, including peptides, sophisticated antibodies, or vectorized siRNA.”

Professor Brian Kim, Vice Chair of Research in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, added: “With its diverse pipeline, Alys’ commitment to advancing the frontiers of immuno-dermatology has the potential to bring transformative solutions to patients worldwide.”

About Alys Pharmaceuticals

Alys Pharmaceuticals, a global leader in immuno-dermatology innovation, was created in February 2024 by world-renowned dermatologists and scientists, including Medixci. Alys, which was formed by combining six asset-focused Medixci companies, has a strong pipeline of cutting-edge platforms and initiatives that address various dermatological indications.

Read also - France-based Pixee Medical Secures $15Million in Funding